PGLA Financials 07/16/2014 09:33:08 Progen Pharma
Post# of 4
Progen Pharmaceuticals Ltd.
Period Ending Jun 30, 2013 Jun 30, 2012 Jun 30, 2011 Jun 30, 2010
Total Revenue 3,213 2,906 3,866 2,417
Cost of Revenue 2,080 1,661 2,233 1,714
Gross Profit 1,133 1,245 1,633 704
Operating Expenses
Research and Development 861 1,492 3,087 4,301
Sales, General and Admin. 1,709 2,193 4,557 7,547
Non-Recurring Items - 2 58 2,233
Other - - - -
Operating Income (1,437) (2,442) (6,069) (13,378)
Income From Continuing Operations
Add'l Income/Expense Items - - - -
Earnings Before Interest and Tax (2,577) (3,527) (6,528) (13,378)
Interest Expense - - - -
Earnings Before Tax (2,577) (3,527) (6,528) (13,378)
Income Tax (662) - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (1,915) (3,527) (6,528) (13,378)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (1,915) (3,527) (6,528) (13,378)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (1,915) (3,527) (6,528) (13,378)